By serial passage of virus (C12N7/08)

Chemistry; metallurgy

(55314)

C12

Biochemistry; beer; spirits; wine; vinegar; microbiology; enzymology; mutation or genetic engineering

(8912)

C12N

icro-organisms or enzymes; compositions thereof (biocides, pest repellants or attractants, or plant growth regulators containing micro-organisms, viruses, microbial fungi, enzymes, fermentates, or substances produced by, or extracted from, micro-organisms or animal material a01n0063000000; medicinal preparations a61k; fertilisers c05f); propagating, preserving, or maintaining micro-organisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000)

(3881)

C12N7

Viruses, e.g. bacteriophages; compositions thereof; preparation or purification thereof (medicinal preparations containing viruses a61k0035760000; preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, a61k0039000000)

(296)

C12N7/08

By serial passage of virus

(3)

Influenza virus strain for producing live influenza intranasal vaccine for adults and children

A/Pert/16/2009(H3N2) strain is produced with the use of genetic reassortation by epidemic virus A/Pert/16/2009(H3N2) mating with the cold-adapter heat-sensitive A/Leningrad/134/17/57(H2N2) strain that is an attenuation donor safe for adults and children. The prepared strain is deposited in the State Collection of Viruses of Ivanovsky Research Institution of Virology of the Russian Academy of Medical Science, No. 2630.

General health-improving agent in treating new growths

Invention refers to medicine, and concerns a general health-improving agent in treating new growths. Substance of the invention covers avirulent bacteria suspension in a stable, irreversible L-form of strain No. 118-L3 with metabolic products in 1-2 % sodium chloride.

Inactivated combined vaccine against cattle infectious rhinotracheitis, virus diarrhoea, rota-, coronavirus disease and leptospirosis

Invention refers to biotechnology. The vaccine contains an active substance and target additives. The active substance is presented with mixed inactivated suspensions of cattle infectious rhinotracheitis virus strain, SVC (State Virus Collection) No. 2333, Herpesviridae family, Alphaherpesviridae subfamily, inactivated suspension of cattle diarrhoea virus strain SVC No. 2336, Flaviviridae family, Pestivirus genus, inactivated suspension of cattle rotavirus strain, SVC No. 2337, Reoviridae family, Rotavirus genus, inactivated suspension of cattle coronavirus strain, SVC No. 2338, Coronaviridae family, Coronavirus genus with activity of each virus strain not less than 106.5 "ТЦД"50 per 1 cm3 of the vaccine. As said active substance, the vaccine also contains mixed inactivated suspension of Leptospira interrogans bacteria cells of Pomona serogroup of strain VGNKI-6, inactivated suspension of Leptospira interrogans bacteria cells of Tarassovi serogroup of strain VGNKI-4, inactivated suspension of Leptospira interrogans bacteria cells of Grippotyphosa serogroup of strain VGNKI-1, inactivated suspension of Leptospira interrogans bacteria cells of Sejroe serogroup of Hardjo strain and inaktivirovannoj suspensions of cells of bacteria Leptospira interrogans of Sejroe serogroup of strain VGNKI-5 taken in the ratio equal to final concentration of each Leptospira strain not less than 270 million microbial cells per 1 cm3 of the vaccine. The vaccine is intended for prevention of cattle infectious diseases accompanied by reproductive disorders of various severities.

Another patent 2513077.